Medical Society Announces Publication of Largest Stem Cell Safety Study to Date
The ICMS announces the publication of the largest stem cell safety study. Using the guidelines put forward by the ICMS, 227 patients were followed for complications after receiving adult stem cell therapies using a novel new protocol. No serious complications were reported.
Portland, OR, December 19, 2009 --(PR.com)-- The International Cellular Medicine Society, a physician professional organization dedicated to the advancement of safe and effective adult stem cell therapies as the practice of medicine, announces the publication of the largest adult stem cell therapy safety study to date. The paper, to be published in the March issue of the peer reviewed journal, Current Stem Cell Research and Therapy, is authored by ICMS members who have pioneered the use of autologous stem cells to treat various orthopedic conditions.
In this landmark study, available at the National Library of Medicine's PubMed on-line system, 227 patients who received adult stem cell therapy as part of usual medical practice were tracked via a strict complications tracking protocol. This complications tracking method was developed by ICMS clinicians and is now incorporated into guidelines authored by the ICMS and its physician members. The results of this study found no evidence of significant stem cell related complications in any of the patients treated, providing further medical evidence of the safety and efficacy of these therapies.
“We believe it to be the largest clinical study ever published on stem cell therapy,” stated study author Christopher J. Centeno, M.D. “This study followed 227patients who received injections of their own stem cells for common orthopedic problems such as knee, hip, shoulder, and ankle arthritis.” The stem cells were grown in a state of the art lab to larger numbers as part of a physician practice. This autologous approach, which avoids the safety and ethical issues seen with embryonic stem cells, utilized adult mesenchymal stem cells. These cells are present in all adults and have been shown to repair cartilage, bone, ligaments, and tendons. The cells were isolated with a novel technique that uses the patient's own growth factors obtained from blood platelets to make the cells usable for therapy. This novel adult stem cell technique is used in the Regenexx stem cell procedure, which utilizes culture expansion and re-implantation of stem cells via a needle. This break through medical procedure has helped patients with various orthopedic conditions avoid the need for more invasive orthopedic surgery.
“This paper advances the ICMS's initiative's to promote safe stem cell therapy worldwide” stated David Audley, executive director of ICMS. This initiative, which the ICMS presented to the physicians and scientists at its annual conference in Las Vegas, Nevada, revolves around the world’s first stem cell therapy registry. The ICMS registry provides strict criteria for the long term, comprehensive tracking of stem cell therapies. “The registry is built to protect and inform patients about the safety and efficacy of these therapies. Clinics that participate show that they have embraced best practices and understand the need for making this data available to patients and their peers.”
###
In this landmark study, available at the National Library of Medicine's PubMed on-line system, 227 patients who received adult stem cell therapy as part of usual medical practice were tracked via a strict complications tracking protocol. This complications tracking method was developed by ICMS clinicians and is now incorporated into guidelines authored by the ICMS and its physician members. The results of this study found no evidence of significant stem cell related complications in any of the patients treated, providing further medical evidence of the safety and efficacy of these therapies.
“We believe it to be the largest clinical study ever published on stem cell therapy,” stated study author Christopher J. Centeno, M.D. “This study followed 227patients who received injections of their own stem cells for common orthopedic problems such as knee, hip, shoulder, and ankle arthritis.” The stem cells were grown in a state of the art lab to larger numbers as part of a physician practice. This autologous approach, which avoids the safety and ethical issues seen with embryonic stem cells, utilized adult mesenchymal stem cells. These cells are present in all adults and have been shown to repair cartilage, bone, ligaments, and tendons. The cells were isolated with a novel technique that uses the patient's own growth factors obtained from blood platelets to make the cells usable for therapy. This novel adult stem cell technique is used in the Regenexx stem cell procedure, which utilizes culture expansion and re-implantation of stem cells via a needle. This break through medical procedure has helped patients with various orthopedic conditions avoid the need for more invasive orthopedic surgery.
“This paper advances the ICMS's initiative's to promote safe stem cell therapy worldwide” stated David Audley, executive director of ICMS. This initiative, which the ICMS presented to the physicians and scientists at its annual conference in Las Vegas, Nevada, revolves around the world’s first stem cell therapy registry. The ICMS registry provides strict criteria for the long term, comprehensive tracking of stem cell therapies. “The registry is built to protect and inform patients about the safety and efficacy of these therapies. Clinics that participate show that they have embraced best practices and understand the need for making this data available to patients and their peers.”
###
Contact
International Cellular Medicine Society
David Audley
503-884-6590
www.cellemdicinesociety.org
David Audley
503-884-6590
www.cellemdicinesociety.org
Contact
Categories